The Food and Drug Administration yesterday approved a mobile medical application to help increase retention in outpatient treatment programs for opioid use disorder. The app can be downloaded to a patient’s mobile device with a prescription from his/her doctor to use while participating in an outpatient treatment program under the care of a health care professional, in conjunction with treatment that includes buprenorphine and contingency management. “As part of our efforts to address the misuse and abuse of opioids, we’re especially focused on new tools and therapies that can help more people with opioid use disorder successfully treat their addiction,” said FDA Commissioner Scott Gottlieb, M.D. “Medical devices, including digital health devices like mobile medical apps, have the potential to play a unique and important role in contributing to these treatment efforts.”

Headline
The Substance Abuse and Mental Health Services Administration July 27 released results from its latest national survey on drug use and mental health. The…
Headline
The AHA’s Bridge to Care initiative highlights how hospitals and health systems are strengthening care transitions and supporting ongoing treatment engagement…
Headline
In this conversation, a team from the University Medical Center New Orleans — LSU School of Medicine’s Benjamin Springgate, M.D., professor of …
Headline
Heidi Bray, DNP, nurse practitioner and hospitalist at Providence St. Peter Hospital, explores how hospitals can improve opioid use disorder treatment through…
Headline
The AHA will host a webinar June 16 at 1 p.m. ET that will share insights from its Bridge to Care Toolkit, designed to help hospitals and health systems…
Headline
The Drug Enforcement Administration today released a final rule implementing provisions from the Restoring Hope for Mental Health and Well-Being Act of 2022,…